Increased T-cell tumor infiltration by mutant LIGHT

Details Increased T-cell tumor infiltration by mutant LIGHT Increased T-cell tumor infiltration by mutant LIGHT

2004-06-10

2010-10-05

Helms, Larry R. (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C424S094100, C424S277100

Reexamination Certificate

active

07807784

ABSTRACT:
Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and reduced metastasis using mutant LIGHT are disclosed.

REFERENCES:
patent: 4797368 (1989-01-01), Carter et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5994523 (1999-11-01), Kawakami et al.
patent: 6048551 (2000-04-01), Hilfinger et al.
patent: 6140467 (2000-10-01), Ware
patent: 6207147 (2001-03-01), Hiserodt et al.
patent: 6475986 (2002-11-01), Aggarwal
patent: 6635743 (2003-10-01), Ebner et al.
patent: 7241576 (2007-07-01), Aggarwal
patent: 2003/0166546 (2003-09-01), Aggarwal
patent: WO 01/79496 (2001-10-01), None
patent: WO 02/32463 (2002-04-01), None
patent: WO 02/34780 (2002-05-01), None
patent: WO 03/040307 (2003-05-01), None
Tamada et al., Nature Medicine, vol. 6, p. 283-289, Mar. 2000.
Boon, T and van der bruggen, P: (1996) Human tumor antigens recognized by T. lymphocytes.J. Exp. Med.183, 725-729.
Cannon, R.E. et al. (1998). Induction of transgene expression in Tg.AC(v-HA-ras) transgenic mice concomitant with DNA hypomethylation.Mol Carcinog21, 244-250.
Chen, L., Linsley, P.S., and Hellstrom, K.E. (1993). Costimulation of T cells for tumor immunity.Immunol Today14, 483-486.
Cyster, J.G. (1999). Chemokines and cell migration in secondary lymphoid organs.Science286, 2098-2102.
Dougall, W.C. et al. (1999). RANK is essential for osteoclast and lymph node development.Genes Dev13, 2412-2424.
Ettinger, R. (2000). The Role of tumor necrosis factor and lymphotoxin in lymphoid organ development.Curr Top Microbiol Immunol251, 203-210.
Fu, Y.X. & Chaplin, D.D. (1999). Development and maturation of secondary lymphoid tissues.Annu Rev Immunol17, 399-433.
Kang, H.S. et al. (2002). Signaling via LTbetaR on the lamina propria stromal cells of the gut is required for IgA production.Nat Immunol3, 576-582.
Kim, D. et al. (2000). Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE.J Exp Med192, 1467-1478.
Kong, Y.Y. et al. (1999). Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.Nature402, 304-309.
Leder, A., Kuo, A., Cardiff, R.D., Sinn, E., and Leder, P. (1990). v-HA-ras transgene abrogates the initiation step in mouse skin tumorgenesis: effects of phorbol esters and terinoic acid.Proc. Natl. Acad. Sci. USA87, 9178-9182.
Mauri, D.N. et al. (1998). LIGHT, a new member of the TNF superfamily, and lymphotixin alpha are ligands for herpes virus entry mediator.Immunity8, 21-30.
Melero, I. et al. (1997). Monoclonal antibodies against the 4-1BB T0cell activation molecule eradicate established tumors.Nat Med3, 682-685.
Ochsenbein, A.F. et al. (2001). Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction.Nature411, 1058-1064.
Ostrand-Rosenberg, S. (1991). Cell-based vaccines for the stimulation of immunity to metastatic cancers.Immunol Rev170, 101-114.
Peace, D.J. et al. (1994). Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.J Exp Med179, 473-479.
Rooney, I.A. et al. (2000). The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells.J Biol Chem275, 14307-1431.
Rosenberg, I.A. et al. (2001). Progress in human tumor immunology and immunotherapy.Nature411, 380-384.
Ruddle, N.H. (1999). Lymphoid neo-organeogenesis: lymphotoxin's role in inflammation and development.Immuno Res19, 119-125.
Sarma, S. et al. (1999). Cytotoxic T lymphocytes to an unmutated tumor rejection antigen PIA: normal development but restrained effector function in vivo.J Exp Med189, 811-820.
Schreiber, H. (1999). Tumor Immunology inFundametal Immunology(ed. Paul, W.E.). Lippincott Rave Press, New York, 1247-1280.
Sha, W.C. et al. (1988). Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice.Nature335, 271-274.
Tamada, K. et al. (2000). Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway.Nat Medl6, 283-289.
Wang, J. et al. (2002). The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function.Eur J Immunol32; 1969.
Wang, J. et al. (2001) The regulation of T cell homeostasis and autoimmunity by T cell derived LIGHT.J clinic. Invest108, 1771-1780.
Wick, M. et al. (1997). Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy.J Exp Med186, 229-238.
Wu, Q. et al. (1999) The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues.J Exp Med190, 629-638.
Ye, Q. et al. (2002) Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival.J Exp Med195, 795-800.
Ye, Z et al. (2002) Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.Nat Med8, 343-348.
Zhai, Y. et al. (1998). LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.Journal of Clinical Investigation102, 1142-1151.
Database WPI (2002): “Section Ch, Week 200203,” Derwent Publications Ltd., Longdon, GB, AN 2002-026029 (WO01/79496-Abstract).
Database WPI (2003): “Section Ch, Week 200340,” Derwent Publications Ltd., Longdon, GB, AN 2003-430659 (WO03/040307-Abstract).
International Search Report issued in PCT/US2004/018631 (2004).
Ware, “Network Communications: Lymphotoxins, Light, and TNF,”Annu. Rev. Immuno., 23: 787-819 (2005).

Affiliated with

Also associated with

Rating

Increased T-cell tumor infiltration by mutant LIGHT does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Increased T-cell tumor infiltration by mutant LIGHT, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Increased T-cell tumor infiltration by mutant LIGHT will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4235649